HIV molecular immunology database
Found 1 matching record:
| HXB2 Location | Gag(162-172) | Gag Epitope Map
View variants at this location |
|||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epitope |
KAFSPEVIPMF
|
Epitope Alignment | |||||||||||||||||||||||||||||||||||||||||||
| Variants |
|
||||||||||||||||||||||||||||||||||||||||||||
| Epitope Name | KF11 | ||||||||||||||||||||||||||||||||||||||||||||
| Species (MHC/HLA) | human(B*57:01, B*57:03) | ||||||||||||||||||||||||||||||||||||||||||||
Showing all: 14 variant(s).
| Variant ID. | 3458 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF |
| Variant Seq. | KgFSPEVIPMF |
| Mutations | A/G |
| Epitope Location | A2G |
| HXB2 Location | A163G |
| Mutation Type | LE: literature escape RCR: replicative capacity reduced SNSF: subtype-specific non-susceptible form |
| Epitope Subtype | B, C |
| Variant Subtype | B, C |
| Method | CD8 T-cell Elispot - IFNy, Relative replication capacity assay, TCR binding |
| Note | Escape variants A163G and S165N are selected in ˜70% of C-infected B*5703-positive subjects, but are not found in B-infected B*5703-positive subjects. The introduction of either or both of these mutations decreases viral replication. There were observable clade-specific differences between C-clade (Botswana) and B-clade (Barbados) 163G. |
| Variant ID. | 3459 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF |
| Variant Seq. | KAFnPEVIPMF |
| Mutations | S/N |
| Epitope Location | S4N |
| HXB2 Location | S165N |
| Mutation Type | LE: literature escape RCR: replicative capacity reduced SNSF: subtype-specific non-susceptible form |
| Epitope Subtype | B, C |
| Variant Subtype | B, C |
| Method | CD8 T-cell Elispot - IFNy, Relative replication capacity assay, TCR binding |
| Note | Escape variants A163G and S165N are selected in ˜70% of C-infected B*5703-positive subjects, but are not found in B-infected B*5703-positive subjects. The introduction of either or both of these mutations decreases viral replication. There are no observable clade-specific differences between C-clade (Botswana) and B-clade (Barbados) 165N. 0% B*5703+ and 2% B*5703- subjects of the B-infected Barbados cohort carried variant KAFnPEVIPMF. |
| Variant ID. | 3461 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF |
| Variant Seq. | KgFnPEVIPMF |
| Mutations | A/G S/N |
| Epitope Location | A2G S4N |
| HXB2 Location | A163G S165N |
| Mutation Type | LE: literature escape RCR: replicative capacity reduced SNSF: subtype-specific non-susceptible form |
| Epitope Subtype | B, C |
| Variant Subtype | B, C |
| Method | CD8 T-cell Elispot - IFNy, Relative replication capacity assay, TCR binding |
| Note | Escape variants A163G and S165N are selected in ˜70% of C-infected B*5703-positive subjects, but are not found in B-infected B*5703-positive subjects, i.e. this double polymorphism is not associated with B*5703. The introduction of either or both of these mutations decreases viral replication. 0% B*5703+ and 1% B*5703- subjects of the B-infected Barbados cohort carried variant KgFnPEVIPMF. |
| Variant ID. | 3462 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF{S} |
| Variant Seq. | KAFSPEVIPMF{t} |
| Mutations | S/T |
| Epitope Location | S+1T |
| HXB2 Location | S173T |
| Mutation Type | LE: literature escape RCR: replicative capacity reduced SNSF: subtype-specific non-susceptible form |
| Epitope Subtype | B, C |
| Variant Subtype | B, C |
| Method | CD8 T-cell Elispot - IFNy, Relative replication capacity assay, TCR binding |
| Note | S173T in combination with either/both A163G and S165N results in reduced a B subtype virus with reduce replicative capacity in B*5703-expressing T cells. There were observable clade-specific differences between C-clade (Botswana) and B-clade (Barbados) 173T. 47% B*5703+ and 23% B*5703- subjects of the Barbados cohort carried variant KAFSPEVIPMF{t} in the +1 position. |
| Variant ID. | 4024 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF |
| Variant Seq. | KsFSPEiIPMF |
| Mutations | A/S V/I |
| Epitope Location | A2S V7I |
| HXB2 Location | A163S V168I |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 7% B*5703+ and 0% B*5703- subjects of the B-infected Barbados cohort carried variant KsFSPEiIPMF. |
| Variant ID. | 4025 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF |
| Variant Seq. | KsFSPEVIPMF |
| Mutations | A/S |
| Epitope Location | A2S |
| HXB2 Location | A163S |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 7% B*5703+ and 1% B*5703- subjects of the B-infected Barbados cohort carried variant KsFSPEVIPMF. |
| Variant ID. | 4026 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF |
| Variant Seq. | KAFkPEVIPMF |
| Mutations | S/K |
| Epitope Location | S4K |
| HXB2 Location | S165K |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 7% B*5703+ and 0% B*5703- subjects of the B-infected Barbados cohort carried variant KAFkPEVIPMF. |
| Variant ID. | 4027 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF |
| Variant Seq. | KAFSPEiIPMF |
| Mutations | V/I |
| Epitope Location | V7I |
| HXB2 Location | V168I |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 0% B*5703+ and 1% B*5703- subjects of the B-infected Barbados cohort carried variant KAFSPEiIPMF. |
| Variant ID. | 4028 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF{S} |
| Variant Seq. | KAFnPEVIPMF{i} |
| Mutations | S/I S/N |
| Epitope Location | S+1I S4N |
| HXB2 Location | S173I S165N |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 7% B*5703+ and 0% B*5703- subjects of the Barbados cohort carried variant KAFnPEVIPMF{i} in the +1 position. |
| Variant ID. | 4029 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF{S} |
| Variant Seq. | KAFSPEVIPMF{a} |
| Mutations | S/A |
| Epitope Location | S+1A |
| HXB2 Location | S173A |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 0% B*5703+ and 1% B*5703- subjects of the Barbados cohort carried variant KAFSPEVIPMF{a} in the +1 position. |
| Variant ID. | 4030 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF{S} |
| Variant Seq. | KgFnPEVIPMF{a} |
| Mutations | S/A A/G S/N |
| Epitope Location | S+1A A2G S4N |
| HXB2 Location | S173A A163G S165N |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 0% B*5703+ and 1% B*5703- subjects of the Barbados cohort carried variant KgFnPEVIPMF{a} in the +1 position. |
| Variant ID. | 4031 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF{S} |
| Variant Seq. | KAFSPEiIPMF{t} |
| Mutations | S/T V/I |
| Epitope Location | S+1T V7I |
| HXB2 Location | S173T V168I |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 7% B*5703+ and 0% B*5703- subjects of the Barbados cohort carried variant KAFSPEiIPMF{t} in the +1 position. |
| Variant ID. | 4032 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF{S} |
| Variant Seq. | KsFSPEVIPMF{t} |
| Mutations | S/T A/S |
| Epitope Location | S+1T A2S |
| HXB2 Location | S173T A163S |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 7% B*5703+ and 0% B*5703- subjects of the Barbados cohort carried variant KsFSPEVIPMF{t} in the +1 position. |
| Variant ID. | 4033 |
|---|---|
| Epitope Seq. | KAFSPEVIPMF{S} |
| Variant Seq. | KnFSPEVIPMF{t} |
| Mutations | S/T A/N |
| Epitope Location | S+1T A2N |
| HXB2 Location | S173T A163N |
| Mutation Type | OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Sequence |
| Note | 0% B*5703+ and 1% B*5703- subjects of the Barbados cohort carried variant KnFSPEVIPMF{t} in the +1 position. |
Payne2014 R. P. Payne, S. Branch, H Kløverpris, P. C. Matthews, C. K. Koofhethile, T. Strong, E. Adland, E. Leitman, J. Frater, T. Ndung'u, E. Hunter, R. Haubrich, B. Mothe, A. Edwards, L. Riddell, F. Chen, P. R. Harrigan, Z. L. Brumme, S. Mallal, M. John, J. P. Jooste, R. Shapiro, S. G. Deeks, B. D. Walker, C. Brander, C. Landis, J. M. Carlson, J. G. Prado, and P. J. R. Goulder. Differential Escape Patterns within the Dominant HLA-B*57:03-Restricted HIV Gag Epitope Reflect Distinct Clade-Specific Functional Constraints. J. Virol., 88(9):4668-4678, May 2014. PubMed ID: 24501417. Show all entries for this paper.